THE FUTURE OF
BLOOD STEM CELL
THERAPIES

OVERVIEW

Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.

Our platform technology for generating self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. As the industry’s first off-the-shelf offering, Garuda’s technology has the potential to cure more than 70 diseases and eliminate dependency on donor or patient cells.

LEADERSHIP

Garuda was founded and is supported by experts in blood stem cell and bone marrow transplants as well as leaders with expertise in bringing transformative medicines to patients.

The Founders

Dhvanit Shah, Ph.D.

Founder, President, & CEO

Former Principal Faculty,
Harvard Stem Cell Institute

Former Associate Member,
Broad Institute of MIT and Harvard

David Scadden

David Scadden, M.D.

Co-Founder

Co-Director,
Harvard Stem Cell Institute

Gerald and Darlene Jordan
Professor of Medicine, Harvard University

Sean Morrison

Sean Morrison, Ph.D.

Co-Founder

Investigator,
Howard Hughes Medical Institute

Director, Children’s Research Institute,
UT Southwestern Medical Center

Board of Directors

Dhvanit Shah, Ph.D.

Founder, President, and CEO
Garuda Therapeutics, Inc.

Eric Aguiar, M.D.

Partner
Aisling Capital

Carl Gordon, Ph.D., CFA

Managing Partner
OrbiMed

Shaan C. Gandhi, M.D., D.Phil.

Director
Northpond Ventures

Rahul Singhvi, Sc.D.

Co-Founder and CEO
National Resilience, Inc.

Scientific Advisory Board

David Scadden

David Scadden, M.D.

Co-Director, Harvard Stem Cell Institute

Gerald and Darlene Jordan Professor of Medicine, Harvard University

Sean Morrison

Sean Morrison, Ph.D.

Investigator, Howard Hughes Medical Institute

Founder & Director, Children’s Research Institute at UT Southwestern Medical Center

Robert Negrin, M.D.

Professor of Medicine, Stanford University

Former Chief of the Division of Blood and Marrow Transplantation, Stanford University

JeromeRitz

Jerome Ritz, M.D.

Executive Director, Connell and O’Reilly Families Cell Manipulation Core Facility, Dana-Farber Cancer Institute

Professor of Medicine, Harvard Medical School

vandenbrink

Marcel van den Brink, M.D., Ph.D.

Head, Division of Hematologic Malignancies &
Alan N. Houghton Chair, Memorial Sloan Kettering Cancer Center

maillard_ivan2 (1)

Ivan Maillard, M.D., Ph.D.

Professor of Hematology-Oncology, University of Pennsylvania School of Medicine

Giorgia Scapin

Giorgia Scapin, Ph.D.

Postdoctoral Fellow, Harvard Medical School

News

November
8
2021

Could new stem cell technology eliminate need for donors’ cells?

“Look at that! Life!” said Deidra Flowers-Williams, a sickle cell disease patient, as she held up a tube with stem cells donated by her sister, Tanisha Flowers. It was just minutes before doctors at the NIH Clinical Center… read more →

September
23
2021

Garuda Therapeutics Launches with $72 Million Series A Financing

First off-the-shelf, long-term durable blood stem cell platform has potential to cure more than 70 diseases, eliminate dependency on donor or patient cells
CAMBRIDGE, Mass. – September 23, 2021 – Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, launched today with an oversubscribed $72 million Series A financing … read more →

September
23
2021

Harvard professor launches stem cell startup with $72M

One platform, 70 diseases and $72 million — these underpin the launch of Garuda Therapeutics, a new stem cell startup founded by Harvard professor Dhvanit Shah… read more →

September
23
2021

Garuda thinks it has cracked the code to off-the-shelf stem cell transplants—and investors are betting $72M to find out

We know blood stem cell transplants are potential cures for serious diseases. The problem is, patients need cells from immune-compatible donors, creating a supply bottleneck that constrains use in some areas and blocks expansion into new diseases. Garuda Therapeutics thinks it may have… read more →

September
23
2021

Looking to make donor cells obsolete, an ex-Harvard researcher gets off-the-shelf stem cell biotech off the ground

A stem cell researcher who spent time at the Harvard Stem Cell Institute, the Broad Institute and Brigham and Women’s Hospital launched a new biotech Thursday, and he’s attracted significant blue-chip investment to get things up and running…. read more →

Join Us

We are seeking team members who share our passion for science, work ethic, and sense of urgency to improve patients’ lives.